 Jennifer Barker
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Addison Disease | 6 | 2012 | 38 | 1.380 |
Why?
| | Diabetes Mellitus, Type 1 | 21 | 2012 | 3937 | 1.250 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2025 | 39 | 1.210 |
Why?
| | Autoantibodies | 15 | 2012 | 1509 | 1.020 |
Why?
| | Autoimmune Diseases | 6 | 2011 | 469 | 0.830 |
Why?
| | Endocrinology | 1 | 2023 | 77 | 0.740 |
Why?
| | Steroid 21-Hydroxylase | 4 | 2012 | 27 | 0.690 |
Why?
| | Endocrine System Diseases | 2 | 2015 | 35 | 0.660 |
Why?
| | Anorexia Nervosa | 1 | 2021 | 79 | 0.610 |
Why?
| | Neonatal Screening | 2 | 2025 | 179 | 0.520 |
Why?
| | Metabolic Diseases | 2 | 2015 | 114 | 0.470 |
Why?
| | Celiac Disease | 4 | 2008 | 311 | 0.440 |
Why?
| | Physicians | 1 | 2023 | 956 | 0.430 |
Why?
| | Emergencies | 1 | 2015 | 174 | 0.410 |
Why?
| | Internship and Residency | 1 | 2023 | 1269 | 0.380 |
Why?
| | Disease Management | 1 | 2015 | 653 | 0.330 |
Why?
| | Child | 21 | 2025 | 22740 | 0.330 |
Why?
| | Turner Syndrome | 2 | 2022 | 65 | 0.330 |
Why?
| | Insulin Antibodies | 2 | 2009 | 103 | 0.320 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2009 | 202 | 0.320 |
Why?
| | HLA-D Antigens | 1 | 2008 | 30 | 0.280 |
Why?
| | HLA-DQ Antigens | 5 | 2009 | 174 | 0.270 |
Why?
| | Polymorphism, Genetic | 2 | 2009 | 615 | 0.260 |
Why?
| | Hypoglycemia | 1 | 2012 | 480 | 0.250 |
Why?
| | Insulin-Secreting Cells | 2 | 2008 | 392 | 0.240 |
Why?
| | Sweetening Agents | 1 | 2007 | 57 | 0.240 |
Why?
| | Preventive Medicine | 1 | 2006 | 39 | 0.240 |
Why?
| | Humans | 37 | 2025 | 145783 | 0.230 |
Why?
| | Primary Prevention | 1 | 2007 | 222 | 0.220 |
Why?
| | Mineralocorticoids | 1 | 2025 | 7 | 0.220 |
Why?
| | Dentate Gyrus | 1 | 2025 | 41 | 0.220 |
Why?
| | Autoimmunity | 5 | 2010 | 933 | 0.210 |
Why?
| | HLA-DR Antigens | 4 | 2009 | 220 | 0.200 |
Why?
| | Disease Progression | 5 | 2012 | 2865 | 0.200 |
Why?
| | HLA-DR3 Antigen | 3 | 2010 | 76 | 0.200 |
Why?
| | Metabolic Syndrome | 1 | 2007 | 361 | 0.190 |
Why?
| | Infant, Newborn | 5 | 2025 | 6465 | 0.190 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 2181 | 0.190 |
Why?
| | Tetany | 1 | 2002 | 2 | 0.180 |
Why?
| | Patient Care | 1 | 2023 | 120 | 0.180 |
Why?
| | Parental Leave | 1 | 2022 | 27 | 0.180 |
Why?
| | Prediabetic State | 2 | 2009 | 250 | 0.180 |
Why?
| | Interferon-alpha | 3 | 2009 | 193 | 0.180 |
Why?
| | Child, Preschool | 8 | 2025 | 11868 | 0.170 |
Why?
| | Adolescent | 13 | 2022 | 22577 | 0.170 |
Why?
| | Insulin | 3 | 2008 | 2516 | 0.170 |
Why?
| | Education, Medical, Graduate | 2 | 2023 | 562 | 0.170 |
Why?
| | Mass Screening | 3 | 2012 | 1361 | 0.170 |
Why?
| | Biomarkers | 2 | 2012 | 4302 | 0.170 |
Why?
| | Glucose | 1 | 2007 | 1049 | 0.170 |
Why?
| | Monosomy | 1 | 2021 | 10 | 0.170 |
Why?
| | Testosterone | 1 | 2025 | 416 | 0.170 |
Why?
| | Genotype | 5 | 2011 | 1857 | 0.160 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 40 | 0.160 |
Why?
| | Sex Chromosome Aberrations | 1 | 2021 | 69 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2025 | 532 | 0.160 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2011 | 18 | 0.150 |
Why?
| | Liver Diseases | 1 | 2022 | 305 | 0.140 |
Why?
| | Islets of Langerhans | 5 | 2009 | 847 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 354 | 0.140 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 147 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 5 | 2011 | 2399 | 0.130 |
Why?
| | Glucose Tolerance Test | 3 | 2009 | 361 | 0.130 |
Why?
| | Male | 14 | 2025 | 73011 | 0.130 |
Why?
| | Risk Factors | 6 | 2012 | 10919 | 0.130 |
Why?
| | Female | 15 | 2025 | 79045 | 0.130 |
Why?
| | Blood Glucose | 2 | 2009 | 2344 | 0.130 |
Why?
| | Hydrocortisone | 2 | 2012 | 298 | 0.120 |
Why?
| | HLA-DR4 Antigen | 2 | 2008 | 74 | 0.120 |
Why?
| | Neurons | 1 | 2025 | 1652 | 0.110 |
Why?
| | Infant | 4 | 2025 | 10091 | 0.110 |
Why?
| | Time Factors | 4 | 2012 | 7134 | 0.110 |
Why?
| | Predictive Value of Tests | 3 | 2012 | 2123 | 0.110 |
Why?
| | Morbidity | 1 | 2015 | 322 | 0.100 |
Why?
| | Administration, Oral | 2 | 2007 | 867 | 0.100 |
Why?
| | Hospitalization | 1 | 2004 | 2461 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2012 | 5428 | 0.100 |
Why?
| | Genetic Testing | 2 | 2006 | 483 | 0.090 |
Why?
| | Renin | 1 | 2012 | 33 | 0.090 |
Why?
| | Haplotypes | 3 | 2011 | 500 | 0.090 |
Why?
| | Global Health | 1 | 2015 | 403 | 0.090 |
Why?
| | Proportional Hazards Models | 2 | 2007 | 1330 | 0.090 |
Why?
| | HLA-B Antigens | 1 | 2011 | 58 | 0.080 |
Why?
| | Gene Frequency | 2 | 2010 | 489 | 0.080 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.080 |
Why?
| | Potassium Channels | 1 | 2011 | 148 | 0.080 |
Why?
| | Alleles | 2 | 2011 | 896 | 0.080 |
Why?
| | Prognosis | 2 | 2012 | 4330 | 0.080 |
Why?
| | Models, Biological | 2 | 2008 | 1764 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 25 | 0.080 |
Why?
| | HLA-DQ beta-Chains | 1 | 2009 | 58 | 0.070 |
Why?
| | Graves Disease | 1 | 2009 | 32 | 0.070 |
Why?
| | Homozygote | 1 | 2009 | 199 | 0.070 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 110 | 0.070 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 157 | 0.070 |
Why?
| | Antibody Specificity | 2 | 2007 | 179 | 0.070 |
Why?
| | Fluoroimmunoassay | 1 | 2007 | 4 | 0.070 |
Why?
| | Diet, Gluten-Free | 1 | 2008 | 56 | 0.060 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 102 | 0.060 |
Why?
| | Transglutaminases | 1 | 2008 | 159 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1043 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2008 | 214 | 0.060 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2006 | 57 | 0.060 |
Why?
| | Adrenal Gland Diseases | 1 | 2006 | 5 | 0.060 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2006 | 16 | 0.060 |
Why?
| | Testosterone Propionate | 1 | 2025 | 1 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2005 | 29 | 0.060 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 35 | 0.050 |
Why?
| | Dihydrotestosterone | 1 | 2025 | 40 | 0.050 |
Why?
| | Autoantigens | 1 | 2008 | 427 | 0.050 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 123 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 12 | 0.050 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2004 | 54 | 0.050 |
Why?
| | Organ Specificity | 1 | 2005 | 309 | 0.050 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 44 | 0.050 |
Why?
| | False Positive Reactions | 1 | 2004 | 123 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 2000 | 0.050 |
Why?
| | Glutamate Decarboxylase | 1 | 2004 | 165 | 0.050 |
Why?
| | Hyperglycemia | 1 | 2008 | 380 | 0.050 |
Why?
| | Biological Evolution | 1 | 2008 | 468 | 0.050 |
Why?
| | HLA Antigens | 1 | 2005 | 240 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 318 | 0.050 |
Why?
| | Neurogenesis | 1 | 2025 | 157 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 167 | 0.050 |
Why?
| | Cohort Studies | 2 | 2022 | 6033 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2005 | 385 | 0.050 |
Why?
| | Cell Survival | 1 | 2025 | 1104 | 0.040 |
Why?
| | Animals | 5 | 2025 | 38102 | 0.040 |
Why?
| | Estradiol | 1 | 2025 | 515 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2007 | 3418 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 1062 | 0.040 |
Why?
| | Karyotype | 1 | 2021 | 19 | 0.040 |
Why?
| | Genitalia | 1 | 2021 | 33 | 0.040 |
Why?
| | Chromosomes, Human, Y | 1 | 2021 | 37 | 0.040 |
Why?
| | Mosaicism | 1 | 2021 | 73 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1101 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 288 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 328 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1851 | 0.040 |
Why?
| | Bone and Bones | 1 | 2002 | 318 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2025 | 2525 | 0.040 |
Why?
| | Proteins | 1 | 2004 | 1023 | 0.030 |
Why?
| | Patient Compliance | 1 | 2002 | 588 | 0.030 |
Why?
| | Prevalence | 1 | 2005 | 2875 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 5925 | 0.030 |
Why?
| | Young Adult | 2 | 2012 | 14254 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1399 | 0.030 |
Why?
| | Pedigree | 2 | 2010 | 515 | 0.030 |
Why?
| | Phenotype | 2 | 2021 | 3170 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5585 | 0.030 |
Why?
| | Mice | 3 | 2008 | 18356 | 0.030 |
Why?
| | Prospective Studies | 2 | 2006 | 8078 | 0.030 |
Why?
| | Reference Values | 2 | 2009 | 798 | 0.030 |
Why?
| | Colorado | 1 | 2004 | 4556 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1407 | 0.030 |
Why?
| | Adult | 5 | 2011 | 40881 | 0.020 |
Why?
| | HLA-B15 Antigen | 1 | 2011 | 12 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 95 | 0.020 |
Why?
| | HLA-B8 Antigen | 1 | 2010 | 11 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 381 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 210 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 12 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6085 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 255 | 0.020 |
Why?
| | Middle Aged | 3 | 2009 | 36309 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 410 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 50 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 260 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2004 | 11794 | 0.020 |
Why?
| | Europium | 1 | 2007 | 2 | 0.020 |
Why?
| | Fluorometry | 1 | 2007 | 19 | 0.020 |
Why?
| | Luminescent Agents | 1 | 2007 | 7 | 0.020 |
Why?
| | Risk | 1 | 2010 | 923 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 175 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 47 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2008 | 616 | 0.010 |
Why?
| | United States | 1 | 2022 | 16126 | 0.010 |
Why?
| | Family Health | 1 | 2005 | 191 | 0.010 |
Why?
| | Lung Diseases | 1 | 2011 | 782 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 649 | 0.010 |
Why?
| | Family | 1 | 2009 | 685 | 0.010 |
Why?
| | Aged | 1 | 2004 | 26217 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1752 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 849 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1812 | 0.010 |
Why?
| | Survival Rate | 1 | 2006 | 2094 | 0.010 |
Why?
|
|
Barker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|